Metastasis-associated protein 1 (MTA1), an epigenetic regulator, plays an important role in prostate cancer progression and metastasis. To investigate the exact role of MTA1 in prostate cancer tumorigenesis and progression to metastasis, we have established MTA1 knockdown cells in various prostate cancer cells lines and performed mechanistic studies in vitro. To test MTA1-targeted strategies for chemoprevention and therapy, we developed appropriate mouse models, namely prostate-specific MTA1-knocked in (MTA1-tg) and MTA1-tg on the background of prostate-specific Pten heterozygosity and loss. Chemopreventive pre-clinical studies were designed using dietary interventions with stilbenes’ supplementations while therapeutic strategies involved combinatorial approaches. Our results demonstrated the contribution of MTA1 in advanced prostate cancer and bone metastasis. Increased levels of oncogenic MTA1-guided molecules identified by ChiP-Seq, including specific MTA1-associated miRNAs may serve as prognostic and predictive biomarkers. We propose a potential for MTA1-targeted strategies in prostate cancer chemoprevention, interception, and therapy.
Dates and Times
Start: 4/15/2021 12:00 PM
End: 4/15/2021 1:00 PM
- MTA1, a specific biomarker and target in prostate cancer.
- Nutritional chemoprevention of prostate cancer.
- Prostate cancer mouse models for preclinical studies.
The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) ™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.